[Skip to Content]
Quiz
Multiple Sclerosis

Multiple Sclerosis Lecture Series: Novel Therapies

Learning Objectives
1. Recognize the unmet needs in effectively treating MS
2. Summarize the proposed mechanisms of progressive MS
3. Recall novel therapies that aim to address treatment gaps
0.75 Credit CME
Stanford Medicine
Published Online: May 16, 2023 Video 39 min 25 sec
Watch Take Quiz

Internet Enduring Material sponsored by Stanford University School of Medicine. Presented by the Stanford University School of Medicine Department of Neurology and Center for Continuing Medical Education.

What are the new innovative treatment strategies indicated for the treatment of MS? Watch the fifth and final lecture in the MS Series to learn about the novel therapies that are at the precipice of transforming the field in patient care. In this talk, Dr Lucas Kipp explores the mechanisms of progressive MS, remyelination, and Epstein Barr Virus treatments.

Sign in to take quiz and track your certificates

To help improve the quality of its educational content and meet applicable education accreditation requirements, the content provider will receive record of your participation and responses to this activity.

Stanford Medicine offers CME on a variety of topics that is evidence-based, references best practices supported by scientific literature and guidelines and is free of commercial bias. Learn more

Video Information

All Rights Reserved. The content of this activity is protected by U.S. and International copyright laws. Reproduction and distribution of its content without written permission of its creator(s) is prohibited.

Financial Support Disclosure Statement: Stanford Medicine adheres to the Standards for Integrity and Independence in Accredited Continuing Education.

There are no relevant financial relationships with ACCME-defined ineligible companies for anyone who was in control of the content of this activity, except those listed in the table below. All of the relevant financial relationships listed for these individuals have been mitigated.

Lucas B. Kipp, MD

Stanford Hospital & Clinics

Course Director, Faculty

Grant or research support-Roche/Genetech/ Grant or research support biogen Idec.

Ruth Adewuya, MD, CHCP

Managing Director, Center for Continuing Medical Education

Stanford University School of Medicine

Planner

Nothing to disclose

Marilyn Mejia, BA

Education Design Coordinator

Stanford University

Planner

Nothing to disclose.

Jamie McDonald, MD

Stanford Health Care

Reviewer

Nothing to disclose

Commercial Support Disclosure Statement: This educational activity is supported in part by an educational grant from Novartis Pharmaceuticals Corporation.

References:
1.
Alotaibi  S, Kennedy  J, Tellier  R, Stephens  D, Banwell  B.  Epstein-Barr virus in pediatric multiple sclerosis.  JAMA. 2004;291(15):1875–1879. doi:10.1001/jama.291.15.1875Google Scholar
2.
Ascherio  A, Munger  KL.  EBV and Autoimmunity.  Curr Top Microbiol Immunol. 2015;390(Pt 1):365–385. doi:10.1007/978-3-319-22822-8_15Google Scholar
3.
Atara Biotherapeutics.  A Phase 1/2, Two-Part, Open-Label Dose-Escalation and Double-Blind, Placebo-Controlled Dose-Expansion Study With an Open-Label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis.  Clinical trial registration. clinicaltrials.gov, July 21 , 2022. https://clinicaltrials.gov/ct2/show/NCT03283826Google Scholar
4.
Bajracharya  R, Caruso  AC, Vella  LJ, Nisbet  RM.  Current and Emerging Strategies for Enhancing Antibody Delivery to the Brain.  Pharmaceutics. 2021; 13(12):2014. https://doi.org/10.3390/pharmaceutics13122014Google Scholar
5.
Biogen. “ A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies. ”  Clinical trial registration. clinicaltrials.gov, April 1 , 2022. https://clinicaltrials.gov/ct2/show/NCT03222973.Google Scholar
6.
Bjornevik  K, Cortese  M, Healy  BC,  et al.  Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.  Science. 2022;375(6578):296–301. doi:10.1126/science.abj8222Google Scholar
7.
Cadavid  D, Balcer  L, Galetta  S,  et al.  Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial.  Lancet Neurol. 2017;16(3):189–199. doi:10.1016/S1474-4422(16)30377-5Google Scholar
8.
Cadavid  D, Mellion  M, Hupperts  R,  et al.  Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.  Lancet Neurol. 2019;18(9):845–856. doi:10.1016/S1474-4422(19)30137-1Google Scholar
9.
Calvi  A, Haider  L, Prados  F, Tur  C, Chard  D, Barkhof  F.  In vivo imaging of chronic active lesions in multiple sclerosis.  Mult Scler. 2022;28(5):683–690. doi:10.1177/1352458520958589Google Scholar
10.
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts. “ Effect of Transorbital Electrical STIMulation of Optic Nerve on Remyelination After an Acute Optic Neuritis. ”  Clinical trial registration. clinicaltrials.gov, August 23 , 2019. https://clinicaltrials.gov/ct2/show/NCT04042363Google Scholar
11.
Cui  X, Snapper  CM.  Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.  Front Immunol. 2021;12:734471. Published 2021 Oct 8 . doi:10.3389/fimmu.2021.734471Google Scholar
12.
Dolgin  E.  BTK blockers make headway in multiple sclerosis.  Nat Biotechnol. 2021;39(1):3–5. doi:10.1038/s41587-020-00790-7Google Scholar
13.
Duffy  CP, McCoy  CE.  The Role of MicroRNAs in Repair Processes in Multiple Sclerosis.  Cells. 2020;9(7):1711. Published 2020 Jul 16 . doi:10.3390/cells9071711Google Scholar
14.
Eisele  P, Fischer  K, Szabo  K, Platten  M and Gass  A (2019)  Characterization of Contrast-Enhancing and Non-contrast-enhancing Multiple Sclerosis Lesions Using Susceptibility-Weighted Imaging.  Front. Neurol. 10:1082. doi: 10.3389/fneur.2019.01082Google Scholar
15.
Filippi  M, Brück  W, Chard  D,  et al.  Association between pathological and MRI findings in multiple sclerosis.  Lancet Neurol. 2019;18(2):198–210. doi:10.1016/S1474-4422(18)30451-4Google Scholar
16.
Fox  RJ, Coffey  CS, Conwit  R,  et al.  Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.  N Engl J Med. 2018;379(9):846–855. doi:10.1056/NEJMoa1803583Google Scholar
17.
Francisco, San. EYETRONIC® - Restoring Vision in Glaucoma. n.d.
18.
Franklin  R., , ffrench-Constant  C.,  Regenerating CNS myelin — from mechanisms to experimental medicines.  Nat Rev Neurosci18, 753–769 (2017). https://doi.org/10.1038/nrn.2017.136Google Scholar

Accreditation
In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation
Stanford Medicine designates this Enduring Material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     
Close
Close
Close
Close

Name Your Search

Save Search
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue